AI Article Synopsis
- Imraldi™ is a newly approved biosimilar of the TNF monoclonal antibody adalimumab, designed for treating inflammatory conditions, and it features a unique autoinjector design.
- A study surveyed 101 nurses and 151 patients in the UK and Germany to compare their preferences for Imraldi against Humira and Enbrel MyClic autoinjectors.
- Results indicated a strong preference for Imraldi, with 85% of nurses and 78% of patients favoring it over Humira, and 86% of nurses and 79% of patients preferring it over Enbrel MyClic, primarily due to its ease of use and button-free design.
Article Abstract
Introduction: Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that features distinct design attributes compared with other biologic TNF inhibitor autoinjectors, such as the Humira (adalimumab) Pen® and Enbrel® (etanercept) MyClic® Pen were developed by the relevant pharmaceutical companies. The aim of this study was to evaluate patients' and nurses' preferences for the Imraldi versus Humira or Enbrel MyClic autoinjectors in the UK and Germany.
Methods: Patients with inflammatory joint or bowel disease and nurses with experience in educating patients with these conditions on self-injection participated in two survey studies, the first comparing the Imraldi and Humira autoinjectors and the second comparing the Imraldi and Enbrel MyClic autoinjectors.
Results: Overall, 101 nurses (UK, n = 50; Germany, n = 51) and 151 patients (UK, n = 90; Germany, n = 61) participated in both studies. In the first study, 85% of nurses and 78% of patients preferred the Imraldi autoinjector over the Humira autoinjector (P < 0.001); in the second study, 86% of nurses and 79% of patients preferred the Imraldi autoinjector over the Enbrel MyClic autoinjector (P < 0.001). Top reasons for preferring the Imraldi autoinjector included ease of use, ease of grip, and its button-free initiation mechanism. Most nurses indicated they would recommend the Imraldi autoinjector over the Humira and Enbrel MyClic autoinjectors, and most patients indicated they would choose the Imraldi autoinjector over the Humira and Enbrel MyClic autoinjectors to continue treatment.
Conclusion: Nurses and patients in the UK and Germany preferred the Imraldi autoinjector over both the Humira and Enbrel MyClic autoinjectors, which may be a consideration, along with other factors, for treatment decisions in the management of patients with inflammatory joint or bowel disease.
Funding: Biogen International GmbH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514039 | PMC |
| http://dx.doi.org/10.1007/s40744-019-0144-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Traditional Chinese Medicine Borneol-Based Polymeric Micelles Intracerebral Drug Delivery System for Precisely Pathogenesis-Adaptive Treatment of Ischemic Stroke.
Adv Sci (Weinh)
January 2025
Frontiers Science Center for Deep Ocean Multispheres and Earth Systems, Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education/Sanya Oceanographic Institution, Ocean University of China, Qingdao/Sanya, 266003/572024, China.
The scarcity of effective neuroprotective agents and the presence of blood-brain barrier (BBB)-mediated extremely inefficient intracerebral drug delivery are predominant obstacles to the treatment of cerebral ischemic stroke (CIS). Herein, ROS-responsive borneol-based amphiphilic polymeric NPs are constructed by using traditional Chinese medicine borneol as functional blocks that served as surface brain-targeting ligand, inner hydrophobic core for efficient drug loading of membrane-permeable calcium chelator BAPTA-AM, and neuroprotective structural component. In MCAO mice, the nanoformulation (polymer: 3.
View Article and Find Full Text PDFIL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.
View Article and Find Full Text PDFAssociation between TLR-2 and TLR-9 gene polymorphisms (rs5743708 and rs5743836) and susceptibility to psoriatic arthritis in Egyptian patients.
Egypt J Immunol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Psoriasis (PsO) is a chronic immune-mediated disease of the skin. Psoriatic arthritis (PsA) is a prevalent chronic inflammatory disease that is associated with joint destruction and disability. The presence of PsO is the single greatest risk factor for the development of PsA.
View Article and Find Full Text PDFSuccessful Treatment of Adventitious Bursitis With Marginal Resection in a 23-Year-Old Patient: A Case Report.
Cureus
December 2024
Department of Orthopedics and Traumatology, Cerrahpasa Faculty of Medicine, Istanbul University - Cerrahpasa, Istanbul, TUR.
Adventitious bursitis is an inflammatory condition affecting bursae. Distinct from primary or infectious bursitis, adventitious bursitis typically develops secondary to conditions such as rheumatoid arthritis, gout, or repetitive joint overuse. The resulting inflammation can lead to pain, swelling, and restricted mobility, significantly impacting patients' quality of life.
View Article and Find Full Text PDFImmunomodulatory effects of novel nano micelle based curcumin in rheumatoid arthritis patients: A double blind randomized clinical trial.
Rheumatol Immunol Res
December 2024
Rheumatologis, Department of Internal Medicine, Ali Ebn Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.
Background And Objectives: Rheumatoid arthritis (RA) is a well-known systemic autoimmune inflammatory disease. This investigation aimed to assess the effects of Sina-curcumin, a novel nano micelle-based curcumin, on immune system responses of RA patients.
Methods: This pilot study is a randomized double blinded, controlled trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!